<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
    
    <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
        <!-- AppResources meta begin -->
        <meta name="paf-app-resources" content="" />
                 <script type="text/javascript">var ncbi_startTime = new Date();</script>
            
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="" />

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK1315" /><meta name="ncbi_domain" content="gene" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK1315/" /><meta name="ncbi_pagename" content="X-Linked Adrenoleukodystrophy - GeneReviews® - NCBI Bookshelf" /><meta name="ncbi_bookparttype" content="chapter" /><meta name="ncbi_app" content="bookshelf" />
        <!-- Logger end -->
        
        <title>X-Linked Adrenoleukodystrophy - GeneReviews® - NCBI Bookshelf</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="/core/jig/1.14.8/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.14.8/js/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="citation_inbook_title" content="GeneReviews® [Internet]" /><meta name="citation_title" content="X-Linked Adrenoleukodystrophy" /><meta name="citation_publisher" content="University of Washington, Seattle" /><meta name="citation_date" content="2018/02/15" /><meta name="citation_author" content="Gerald V Raymond" /><meta name="citation_author" content="Ann B Moser" /><meta name="citation_author" content="Ali Fatemi" /><meta name="citation_pmid" content="20301491" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK1315/" /><meta name="citation_keywords" content="X-ALD" /><meta name="citation_keywords" content="X-ALD" /><meta name="citation_keywords" content="Adrenomyeloneuropathy (AMN)" /><meta name="citation_keywords" content="Childhood Cerebral Form" /><meta name="citation_keywords" content="Addison Disease Only" /><meta name="citation_keywords" content="ATP-binding cassette sub-family D member 1" /><meta name="citation_keywords" content="ABCD1" /><meta name="citation_keywords" content="X-Linked Adrenoleukodystrophy" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="X-Linked Adrenoleukodystrophy" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="University of Washington, Seattle" /><meta name="DC.Contributor" content="Gerald V Raymond" /><meta name="DC.Contributor" content="Ann B Moser" /><meta name="DC.Contributor" content="Ali Fatemi" /><meta name="DC.Date" content="2018/02/15" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK1315/" /><meta name="description" content="X-linked adrenoleukodystrophy (X-ALD) affects the nervous system white matter and the adrenal cortex. Three main phenotypes are seen in affected males:" /><meta name="og:title" content="X-Linked Adrenoleukodystrophy" /><meta name="og:type" content="book" /><meta name="og:description" content="X-linked adrenoleukodystrophy (X-ALD) affects the nervous system white matter and the adrenal cortex. Three main phenotypes are seen in affected males:" /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK1315/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/gene/x-ald/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK1315/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books_print.min.css" type="text/css" media="print" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace}  .first-line-outdent .bk_ref {display: inline}  .body-content h2, .body-content .h2  {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list  .graphic {display:inline-block !important} .temp-labeled-list  img{width:100%}</style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/large-obj-scrollbars.min.js"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/books.min.js"> </script><meta name="book-collection" content="NONE" />

        <!-- Page meta end -->
    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE894EF1E040A521000000000240010F.m_12" />
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4098876/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/4008682/3881636/3579733/4062871/12930/3964959/3854974/36029/4128070/9685/3549676/3609192/3609193/3609213/3395586.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3411343/3882866.css" media="print" /></head>
    <body class="book-part">
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	<p class="nojs">
	<strong>Warning:</strong>
	The NCBI web site requires JavaScript to function. 
	<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
	</p>
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id="navcontent"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt"><a class="ui-ncbimenu-link-first" href="/" role="banner" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="/account/" id="sign_in">Sign in to NCBI</a><a href="/account/signout/" id="sign_out" style="display:none">Sign Out</a></div></div>
                            <div class="header">
    <div class="res_logo"><h1 class="res_name"><a href="/books/" title="Bookshelf home">Bookshelf</a></h1><h2 class="res_tagline"></h2></div>
    <div class="search"><form method="get" action="/books/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="books" selected="selected" class="last" data-ac_dict="bookshelf-search">Books</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books" data-ac_dict="bookshelf-search">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc">PMC</option><option value="popset">PopSet</option><option value="probe">Probe</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sparcle">Sparcle</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search Books. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'bookshelf-search',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'no'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="/books/browse/">Browse Titles</a>
                    </li><li>
                        <a href="/books/advanced/">Advanced</a>
                    </li><li class="help">
                        <a href="/books/NBK3833/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <!-- Custom content 1 -->
<div class="col1">
    
</div>

<div class="container">
    <div id="maincontent" class="content eight_col col">
        <!-- Custom content in the left column above book nav -->
        <div class="col2">
            
        </div>
        
        <!-- Book content -->
        

        <!-- Custom content between navigation and content -->
        <div class="col3">
            
        </div>
        
        <div class="document">
            <div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. </p></div><div class="iconblock clearfix whole_rhythm no_top_margin bk_noprnt"><a class="img_link icnblk_img" title="All GeneReviews" href="/books/n/gene/"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" alt="Cover of GeneReviews®" height="100px" width="80px" /></a><div class="icnblk_cntnt eight_col"><h2>GeneReviews<sup>®</sup> [Internet].</h2><a data-jig="ncbitoggler" href="#__NBK1315_dtls__">Show details</a><div style="display:none" class="ui-widget" id="__NBK1315_dtls__"><div>Adam MP, Ardinger HH, Pagon RA, et al., editors.</div><div>Seattle (WA): <a href="http://www.washington.edu" ref="pagearea=page-banner&amp;targetsite=external&amp;targetcat=link&amp;targettype=publisher">University of Washington, Seattle</a>; 1993-2019.</div></div><div class="half_rhythm"><ul class="inline_list"><li style="margin-right:1em"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a></li></ul></div><div class="bk_noprnt"><form method="get" action="/books/n/gene/" id="bk_srch"><div class="bk_search"><label for="bk_term" class="offscreen_noflow">Search term</label><input type="text" title="Search GeneReviews" id="bk_term" name="term" value="" data-jig="ncbiclearbutton" /> <input type="submit" class="jig-ncbibutton" value="Search GeneReviews" submit="false" style="padding: 0.1em 0.4em;" /></div></form><div><ul class="inline_list"><li><a href="/books/n/gene/advanced/">GeneReviews Advanced Search</a></li><li style="margin-left:.5em"><a href="/books/n/gene/helpadvsearch/">Help</a></li></ul></div></div></div><div class="icnblk_cntnt two_col"><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/x-ag/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/xla/" title="Next page in this title">Next &gt;</a></div></div></div></div></div>
            <div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK1315_"><span class="title" itemprop="name">X-Linked Adrenoleukodystrophy</span></h1><div itemprop="alternativeHeadline" class="subtitle whole_rhythm">Synonym: X-ALD</div><p class="contrib-group"><span itemprop="author">Gerald V Raymond</span>, MD, <span itemprop="author">Ann B Moser</span>, BA, and <span itemprop="author">Ali Fatemi</span>, MD.</p><a data-jig="ncbitoggler" href="#__NBK1315_ai__" style="border:0;text-decoration:none">Author Information</a><div style="display:none" class="ui-widget" id="__NBK1315_ai__"><div class="contrib half_rhythm"><span itemprop="author">Gerald V Raymond</span>, MD<div class="affiliation small">Pediatric Neurology<br />Penn State Hershey Medical Center<br />Hershey, Pennsylvania<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ude.usp.htlaehetatsnnep@dnomyarg" class="oemail">ude.usp.htlaehetatsnnep@dnomyarg</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Ann B Moser</span>, BA<div class="affiliation small">Department of Neurogenetics<br />Kennedy Krieger Institute<br />Baltimore, Maryland<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="gro.regeirkydennek@aresom" class="oemail">gro.regeirkydennek@aresom</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Ali Fatemi</span>, MD<div class="affiliation small">Department of Neurogenetics<br />Kennedy Krieger Institute<br />Baltimore, Maryland<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="gro.regeirkydennek@imetaf" class="oemail">gro.regeirkydennek@imetaf</a></div></div></div></div><p class="small">Initial Posting: <span itemprop="datePublished">March 26, 1999</span>; Last Update: <span itemprop="dateModified">February 15, 2018</span>.</p><p><em>Estimated reading time: 23 minutes</em></p></div><div class="jig-ncbiinpagenav body-content whole_rhythm" data-jigconfig="allHeadingLevels: ['h2'],smoothScroll: false" itemprop="text"><div id="x-ald.Summary" itemprop="description"><h2 id="_x-ald_Summary_">Summary</h2><div><h4 class="inline">Clinical characteristics.</h4><p><a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a> adrenoleukodystrophy (X-ALD) affects the nervous system white matter and the adrenal cortex. Three main phenotypes are seen in <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> males:</p><ul><li class="half_rhythm"><div>The childhood cerebral form manifests most commonly between ages four and eight years. It initially resembles attention-deficit disorder or hyperactivity; progressive impairment of cognition, behavior, vision, hearing, and motor function follow the initial symptoms and often lead to total disability within six months to two years. Most individuals have impaired adrenocortical function at the time that neurologic disturbances are first noted.</div></li><li class="half_rhythm"><div>Adrenomyeloneuropathy (AMN) manifests most commonly in an individual in his twenties or middle age as progressive stiffness and weakness of the legs, sphincter disturbances, sexual dysfunction, and often, impaired adrenocortical function; all symptoms are progressive over decades.</div></li><li class="half_rhythm"><div>"Addison disease only" presents with primary adrenocortical insufficiency between age two years and adulthood and most commonly by age 7.5 years, without evidence of neurologic abnormality; however, some degree of neurologic disability (most commonly AMN) usually develops by middle age.</div></li></ul><p>More than 20% of female carriers develop mild-to-moderate spastic paraparesis in middle age or later. Adrenal function is usually normal.</p></div><div><h4 class="inline">Diagnosis/testing.</h4><p>The diagnosis of X-ALD is established in a male <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with suggestive clinical findings and elevated very long chain fatty acids (VLCFA). MRI is always abnormal in boys with cerebral disease and often provides the first diagnostic lead. The diagnosis of X-ALD is usually established in a female proband with detection of a <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> <i>ABCD1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> and elevated VLCFA.</p></div><div><h4 class="inline">Management.</h4><p><i>Treatment of manifestations:</i> Corticosteroid replacement therapy is essential for those with adrenal insufficiency. Affected boys benefit from the general supportive care of parents and psychological and educational support. Physical therapy, management of urologic complications, and family and vocational counseling are of value for men with AMN.</p><p><i>Surveillance:</i> For males with X-ALD, periodic reevaluation of adrenocortical function (currently suggested at 6-month intervals) and MRIs for detection of early cerebral disease (yearly until age 3 years and then at 6-month intervals until age 10 years).</p><p><i>Evaluation of relatives at risk:</i> Early identification of asymptomatic or minimally symptomatic at-risk males permits timely treatment of adrenal insufficiency.</p></div><div><h4 class="inline">Genetic counseling.</h4><p>X-ALD is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a> manner. About 95% of persons representing index cases have inherited the <i>ABCD1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> from one parent; at least 4.1% of individuals with X-ALD have a <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> pathogenic variant. Affected males transmit the <i>ABCD1</i> pathogenic variant to all of their daughters and none of their sons. Carrier females have a 50% chance of transmitting the <i>ABCD1</i> pathogenic variant in each pregnancy. Males who inherit the pathogenic variant will be <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>; females who inherit it are carriers and will usually not be seriously affected. The phenotypic expression and prognosis of an affected male is unpredictably variable. Heterozygote (<a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a>) detection for at-risk female relatives and prenatal testing or preimplantation diagnosis for pregnancies at increased risk are possible if the pathogenic variant in the family is known.</p></div></div><div id="x-ald.GeneReview_Scope"><h2 id="_x-ald_GeneReview_Scope_"><i>GeneReview</i> Scope</h2><div id="x-ald.Td" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1315/table/x-ald.Td/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__x-ald.Td_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_x-ald.Td_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">X-Linked Adrenoleukodystrophy: Included Phenotypes&#x000a0;<sup>1</sup></th></tr></thead><tbody><tr><td headers="hd_h_x-ald.Td_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><ul><li class="half_rhythm"><div>Childhood cerebral form</div></li><li class="half_rhythm"><div>Adrenomyeloneuropathy (AMN)</div></li><li class="half_rhythm"><div>Addison disease only</div></li></ul>
</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">For synonyms and outdated names see <a href="#x-ald.Nomenclature">Nomenclature</a>.</p></div></dd><dt>1. </dt><dd><div id="x-ald.TF.d.1"><p class="no_margin">For other genetic causes of these phenotypes see <a href="#x-ald.Differential_Diagnosis">Differential Diagnosis</a>.</p></div></dd></dl></div></div></div></div><div id="x-ald.Diagnosis"><h2 id="_x-ald_Diagnosis_">Diagnosis</h2><div id="x-ald.Suggestive_Findings"><h3>Suggestive Findings</h3><p>The diagnosis of <a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a> adrenoleukodystrophy (X-ALD) <b>should be suspected</b> in an individual in one of four clinical settings and in infants with a positive newborn screen result.</p><p><b>Clinical settings</b></p><ul><li class="half_rhythm"><div><b>Boys</b> with symptoms of attention-deficit disorder (ADD) who also show signs of dementia, progressive behavioral disturbance, vision loss, difficulty in understanding spoken language, worsening handwriting, incoordination, or other neurologic disturbances</div></li><li class="half_rhythm"><div><b>Young or middle-aged men</b> with progressive gait disorders, leg stiffness or weakness, abnormalities of sphincter control, and sexual dysfunction, with or without adrenal insufficiency or cognitive or behavioral deficits</div></li><li class="half_rhythm"><div><b>All males</b> with primary adrenocortical insufficiency, with or without evidence of neurologic abnormality</div></li><li class="half_rhythm"><div><b>Adult women</b> with progressive paraparesis, abnormalities of sphincter control, and sensory disturbances mainly affecting the legs. It may be difficult to establish the diagnosis of X-ALD in a female with a negative family history. Diagnosis is based on clinical features (most commonly progressive spastic paraparesis) and a panel of laboratory tests.</div></li></ul><p><b>Neuroimaging.</b> Brain MRI is always abnormal in neurologically symptomatic males with cerebral disease and often provides the first diagnostic lead. In approximately 85% of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals, MRI shows a characteristic pattern of symmetric enhanced T<sub>2</sub> signal in the parieto-occipital region with contrast enhancement at the advancing margin.</p><p><b>Newborn screening.</b> In February 2016, <a class="def" href="/books/n/gene/glossary/def-item/newborn-screening/">newborn screening</a> for X-ALD was added to the recommended uniform screening panel in the United States. At present several states have added it to their newborn blood spot screening. New York state began screening in 2012 and all newborns are screened using a three-tiered algorithm: the first two tiers involve biochemical testing (i.e., tandem mass spectrometry [MS/MS] of C26:0; in all those with an out-of-range result, C26:0 LPC is measured using HPLC-MS/MS) [<a class="bk_pop" href="#x-ald.REF.vogel.2015.599">Vogel et al 2015</a>] (see <a class="figpopup" href="/books/NBK1315/table/x-ald.T.plasma_very_long_chain_fatty_aci/?report=objectonly" target="object" rid-figpopup="figxaldTplasmaverylongchainfattyaci" rid-ob="figobxaldTplasmaverylongchainfattyaci">Table 1</a>). The third tier is <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> to confirm the diagnosis (see <a href="#x-ald.Establishing_the_Diagnosis">Establishing the Diagnosis</a>, <b>Molecular genetic testing</b>). Other states have chosen varying strategies.</p></div><div id="x-ald.Establishing_the_Diagnosis"><h3>Establishing the Diagnosis</h3><p><b>Male <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> The diagnosis of X-ALD <b>is established</b> in a male proband with suggestive clinical findings and elevated very long chain fatty acids (VLCFA). Measurement of VLCFA is sufficient to establish the diagnosis of X-ALD in the majority of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> males. Rarely, when measurement of VLCFA is inconclusive, detection of a <a class="def" href="/books/n/gene/glossary/def-item/hemizygous/">hemizygous</a> <i>ABCD1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> on <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> is required to confirm the diagnosis (see <a class="figpopup" href="/books/NBK1315/table/x-ald.T.molecular_genetic_testing_used_i/?report=objectonly" target="object" rid-figpopup="figxaldTmoleculargenetictestingusedi" rid-ob="figobxaldTmoleculargenetictestingusedi">Table 2</a>).</p><p><b>Female <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b>. The diagnosis of X-ALD <b>is usually established</b> in a female proband by detection of a <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> <i>ABCD1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> and elevated VLCFA.</p><p>A female with childhood-onset X-ALD caused by <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> pathogenic variants in <i>ABCD1</i> involving a maternally inherited <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>ABCD1</i> in combination with a paternally derived <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> of <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> Xq27 has been reported [<a class="bk_pop" href="#x-ald.REF.hershkovitz.2002.234">Hershkovitz et al 2002</a>].</p><p><b>Very long chain fatty acids (VLCFA).</b> Three parameters are analyzed:</p><ul><li class="half_rhythm"><div>Concentration of C26:0</div></li><li class="half_rhythm"><div>Ratio of C24:0 to C22:0</div></li><li class="half_rhythm"><div>Ratio of C26:0 to C22:0</div></li></ul><p><a class="figpopup" href="/books/NBK1315/table/x-ald.T.plasma_very_long_chain_fatty_aci/?report=objectonly" target="object" rid-figpopup="figxaldTplasmaverylongchainfattyaci" rid-ob="figobxaldTplasmaverylongchainfattyaci">Table 1</a> summarizes mean results for normal controls, <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> males, and <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> females. The VLCFA assay is performed in a limited number of laboratories worldwide.</p><ul><li class="half_rhythm"><div><b>Males.</b> The plasma concentration of very long chain fatty acids (VLCFA) is abnormal in males with X-ALD, irrespective of age. All three parameters are elevated in the majority of males, though some variation is observed. The discriminant function reported in <a class="bk_pop" href="#x-ald.REF.moser.1999.100">Moser et al [1999]</a> fully separates normal control males from <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> males.</div></li><li class="half_rhythm"><div><b>Females.</b> Increased concentration of VLCFA in plasma and/or cultured skin fibroblasts is present in approximately 85% of females; 20% of known carriers have normal plasma concentration of VLCFA. The discriminant function reported in <a class="bk_pop" href="#x-ald.REF.moser.1999.100">Moser et al [1999]</a> is not able to distinguish all carriers from the normal control range. Note: The discriminant function published by <a class="bk_pop" href="#x-ald.REF.moser.1999.100">Moser et al [1999]</a> is applicable to the specific method used at that time. A different discriminant function would need to be derived for other methods of extraction and analysis.</div></li></ul><div id="x-ald.T.plasma_very_long_chain_fatty_aci" class="table"><h3><span class="label">Table 1. </span></h3><div class="caption"><p>Plasma Very Long Chain Fatty Acid (VLCFA) Values in X-ALD</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1315/table/x-ald.T.plasma_very_long_chain_fatty_aci/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__x-ald.T.plasma_very_long_chain_fatty_aci_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_x-ald.T.plasma_very_long_chain_fatty_aci_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">VLCFA</th><th id="hd_h_x-ald.T.plasma_very_long_chain_fatty_aci_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Normal</th><th id="hd_h_x-ald.T.plasma_very_long_chain_fatty_aci_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Males with X-ALD</th><th id="hd_h_x-ald.T.plasma_very_long_chain_fatty_aci_1_1_1_4" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Obligate Female Carriers</th></tr></thead><tbody><tr><td headers="hd_h_x-ald.T.plasma_very_long_chain_fatty_aci_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">C26:0 &#x000b5;g/mL&#x000a0;<sup>1</sup></td><td headers="hd_h_x-ald.T.plasma_very_long_chain_fatty_aci_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">0.23+0.09</td><td headers="hd_h_x-ald.T.plasma_very_long_chain_fatty_aci_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">1.30+0.45</td><td headers="hd_h_x-ald.T.plasma_very_long_chain_fatty_aci_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">0.68+0.29</td></tr><tr><td headers="hd_h_x-ald.T.plasma_very_long_chain_fatty_aci_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">C24:0/C22:0&#x000a0;<sup>2</sup></td><td headers="hd_h_x-ald.T.plasma_very_long_chain_fatty_aci_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">0.84+0.10</td><td headers="hd_h_x-ald.T.plasma_very_long_chain_fatty_aci_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">1.71+0.23</td><td headers="hd_h_x-ald.T.plasma_very_long_chain_fatty_aci_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">1.30+0.19</td></tr><tr><td headers="hd_h_x-ald.T.plasma_very_long_chain_fatty_aci_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">C26:0/C22:0&#x000a0;<sup>2</sup></td><td headers="hd_h_x-ald.T.plasma_very_long_chain_fatty_aci_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">0.01+0.004</td><td headers="hd_h_x-ald.T.plasma_very_long_chain_fatty_aci_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">0.07+0.03</td><td headers="hd_h_x-ald.T.plasma_very_long_chain_fatty_aci_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">0.04+0.02</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin"><a class="bk_pop" href="#x-ald.REF.steinberg.2008">Steinberg et al [2008]</a></p></div></dd><dt>1. </dt><dd><div id="x-ald.TF.1.1"><p class="no_margin">The concentration of C26:0 is reported as &#x000b5;g/mL; some laboratories report this as &#x000b5;mol/L.</p></div></dd><dt>2. </dt><dd><div id="x-ald.TF.1.2"><p class="no_margin">Lorenzo's oil, a mixture of erucic and oleic acids, is used therapeutically to normalize VLCFA levels. Thus erucic acid (C22:1) levels are routinely reported when measuring plasma VLCFA. Certain oils used in cooking, such as mustard seed oil, have naturally high levels of erucic acid and thus can lead to an elevation similar to that observed with Lorenzo's oil therapy.</p></div></dd></dl></div></div></div><div id="x-ald.Molecular_Genetic_Testing"><h4>Molecular Genetic Testing</h4><p>Molecular genetic testing approaches can include <b>single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing</b>, use of a <b><a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a>,</b> and <b>more comprehensive <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing</b>:</p><ul><li class="half_rhythm"><div class="half_rhythm"><b>Single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing.</b> Sequence analysis of <i>ABCD1</i> is performed first followed by gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> if no <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is found.</div></li><li class="half_rhythm"><div class="half_rhythm"><b>A <a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a></b> that includes <i>ABCD1</i> and other genes of interest (see <a href="#x-ald.Differential_Diagnosis">Differential Diagnosis</a>) may be considered. Note: (1) The genes included in the panel and the diagnostic <a class="def" href="/books/n/gene/glossary/def-item/sensitivity/">sensitivity</a> of the testing used for each <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> vary by laboratory and are likely to change over time. (2) Some multigene panels may include genes not associated with the condition discussed in this <i>GeneReview</i>; thus, clinicians need to determine which multigene panel is most likely to identify the genetic cause of the condition at the most reasonable cost while limiting identification of variants of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a> and pathogenic variants in genes that do not explain the underlying <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>. (3) In some laboratories, panel options may include a custom laboratory-designed panel and/or custom phenotype-focused <a class="def" href="/books/n/gene/glossary/def-item/exome/">exome</a> analysis that includes genes specified by the clinician. (4) Methods used in a panel may include <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a>, <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>, and/or other non-sequencing-based tests.</div><div class="half_rhythm">For an introduction to multigene panels click <a href="/books/n/gene/app5/#app5.Multigene_Panels">here</a>. More detailed information for clinicians ordering genetic tests can be found <a href="/books/n/gene/app5/#app5.Multigene_Panels_FAQs">here</a>.</div><div class="half_rhythm">Note: Analysis of <i>ABCD1</i> by <a class="def" href="/books/n/gene/glossary/def-item/next-generation-sequencing/">next-generation sequencing</a> is complicated by the presence of pseudogenes <i>ABCD1P1</i>, <i>ABCD1P2</i>, <i>ABCD1P3</i>, <i>ABCD1P4</i>, and <i>ABCD1P5</i>.</div></li><li class="half_rhythm"><div class="half_rhythm"><b>More comprehensive <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing</b> (when available) including <a class="def" href="/books/n/gene/glossary/def-item/exome-sequencing/">exome sequencing</a> and <a class="def" href="/books/n/gene/glossary/def-item/genome-sequencing/">genome sequencing</a> may be considered. Such testing may provide or suggest a diagnosis not previously considered (e.g., mutation of a different <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> or genes that results in a similar clinical presentation).</div><div class="half_rhythm">For an introduction to comprehensive <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing click <a href="/books/n/gene/app5/#app5.Comprehensive_Genomic_Testing">here</a>. More detailed information for clinicians ordering genomic testing can be found <a href="/books/n/gene/app5/#app5.Comprehensive_Genomic_Testing_1">here</a>.</div></li></ul><p>Note: The clinical consequence of pathogenic or suspected pathogenic variants in <i>ABCD1</i> may be determined by clinical correlation with very long chain fatty acid analysis [<a class="bk_pop" href="#x-ald.REF.schackmann.2016.123">Schackmann et al 2016</a>].</p><div id="x-ald.T.molecular_genetic_testing_used_i" class="table"><h3><span class="label">Table 2. </span></h3><div class="caption"><p>Molecular Genetic Testing Used in X-ALD</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1315/table/x-ald.T.molecular_genetic_testing_used_i/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__x-ald.T.molecular_genetic_testing_used_i_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_x-ald.T.molecular_genetic_testing_used_i_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Gene&#x000a0;<sup>1</sup></th><th id="hd_h_x-ald.T.molecular_genetic_testing_used_i_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Method</th><th id="hd_h_x-ald.T.molecular_genetic_testing_used_i_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Proportion of Probands with a Pathogenic Variant&#x000a0;<sup>2</sup> Detectable by Method</th></tr></thead><tbody><tr><td headers="hd_h_x-ald.T.molecular_genetic_testing_used_i_1_1_1_1" rowspan="2" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><i>ABCD1</i></td><td headers="hd_h_x-ald.T.molecular_genetic_testing_used_i_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Sequence analysis&#x000a0;<sup>3,&#x000a0;4</sup></td><td headers="hd_h_x-ald.T.molecular_genetic_testing_used_i_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">97%&#x000a0;<sup>5</sup></td></tr><tr><td headers="hd_h_x-ald.T.molecular_genetic_testing_used_i_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>&#x000a0;<sup>6</sup></td><td headers="hd_h_x-ald.T.molecular_genetic_testing_used_i_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">3%&#x000a0;<sup>5</sup></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="x-ald.TF.2.1"><p class="no_margin">See <a href="/books/NBK1315/#x-ald.molgen.TA">Table A. Genes and Databases</a> for <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> and protein.</p></div></dd><dt>2. </dt><dd><div id="x-ald.TF.2.2"><p class="no_margin">See <a href="#x-ald.Molecular_Genetics">Molecular Genetics</a> for information on allelic variants detected in this <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>.</p></div></dd><dt>3. </dt><dd><div id="x-ald.TF.2.3"><p class="no_margin">Sequence analysis detects variants that are benign, likely benign, of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a>, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a>, <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a>, and <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> variants; typically, <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> or whole-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> deletions/duplications are not detected. For issues to consider in interpretation of <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> results, click <a href="/books/n/gene/app2/">here</a>.</p></div></dd><dt>4. </dt><dd><div id="x-ald.TF.2.4"><p class="no_margin">Lack of amplification by <a class="def" href="/books/n/gene/glossary/def-item/pcr/">PCR</a> prior to <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> can suggest a putative (multi)<a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> or whole-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> on the X <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> in <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> males; confirmation requires additional testing by gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>.</p></div></dd><dt>5. </dt><dd><div id="x-ald.TF.2.5"><p class="no_margin">In <a class="def" href="/books/n/gene/glossary/def-item/hemizygous/">hemizygous</a> males and obligate heterozygotes: 399/423 had pathogenic variants, likely pathogenic variants, or variants of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a> detected by <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a>; 19/423 had pathogenic variants identified by <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>; in one of the five remaining individuals with no identifiable <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, <a class="def" href="/books/n/gene/glossary/def-item/southern-blot/">Southern blot</a> analysis suggested a duplication or rearrangement [Steinberg, Moser, and Raymond, personal observation; <a href="http://adrenoleukodystrophy.info/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">adrenoleukodystrophy.info</a>].</p></div></dd><dt>6. </dt><dd><div id="x-ald.TF.2.6"><p class="no_margin">Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> detects intragenic deletions or duplications. Methods used may include <a class="def" href="/books/n/gene/glossary/def-item/quantitative-pcr/">quantitative PCR</a>, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and a <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>-targeted microarray designed to detect single-<a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> deletions or duplications.</p></div></dd></dl></div></div></div></div></div></div><div id="x-ald.Clinical_Characteristics"><h2 id="_x-ald_Clinical_Characteristics_">Clinical Characteristics</h2><div id="x-ald.Clinical_Description"><h3>Clinical Description</h3><p>The range of phenotypic expression in <a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a> adrenoleukodystrophy (X-ALD) is wide and cannot be predicted through levels of VLCFA or family history. Widely varying phenotypes often co-occur in a single kindred or sibship [<a class="bk_pop" href="#x-ald.REF.moser.2001">Moser et al 2001</a>]. Some individuals with X-ALD remain asymptomatic until their adult years.</p><div id="x-ald.Presentations_Most_Commonly_Seen_i"><h4>Presentations Most Commonly Seen in Affected Males</h4><p><b>Symptom set 1 (childhood cerebral forms; ~35% of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals).</b> Presentation occurs most commonly between age four and eight years, with a peak at age seven years. It virtually never occurs before age three years.</p><p>Affected boys present with behavioral or learning deficits, often diagnosed as attention-deficit disorder or hyperactivity, which may respond to stimulant medication. These behaviors may persist for months or longer, and are followed by symptoms suggestive of a more serious underlying disorder including: "spacing out" in school (inattention, deterioration in handwriting skills, and diminishing school performance); difficulty in understanding speech (though sound perception is normal); difficulty in reading, spatial orientation, and comprehension of written material; clumsiness; visual disturbances and occasionally diplopia; and aggressive or disinhibited behavior.</p><p>Brain MRI examination performed at this time can be strikingly abnormal even when symptoms are relatively mild.</p><p>In some boys, seizures may be the first manifestation.</p><p>While variable, the rate of progression may be rapid, with total disability in six months to two years followed by death at varying ages.</p><p>Most individuals have impaired adrenocortical function at the time that neurologic disturbances are first noted.</p><p><b>Symptom set 2 (adrenomyeloneuropathy [AMN]; ~40%-45%).</b> The typical presentation is a man in his twenties or middle age who develops progressive stiffness and weakness in the legs, abnormalities of sphincter control, and sexual dysfunction. All symptoms are progressive over decades.</p><p>Approximately 40%-45% of individuals with AMN show some degree of brain involvement on MRI or clinical examination. In 10%-20% of individuals with AMN, brain involvement becomes severely progressive and leads to serious cognitive and behavioral disturbances that may progress to total disability and death.</p><p>Approximately 70% of men with AMN have impaired adrenocortical function at the time that neurologic symptoms are first noted.</p><p><b>Symptom set 3 (Addison disease only; ~10%).</b> Males present with signs of adrenal insufficiency between age two years and adulthood, most commonly by age 7.5 years. Presenting signs include unexplained vomiting and weakness or coma, leading to the diagnosis of Addison disease. Increased skin pigmentation resulting from excessive ACTH secretion is variably present.</p><p>Most males who present initially with adrenocortical insufficiency do not develop evidence of AMN until middle age.</p><p><b>Overall, adrenal function</b> is abnormal in 90% of neurologically symptomatic boys and in 70% of men with adrenomyeloneuropathy. It is usually normal in <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> females. The most sensitive indicators of adrenal dysfunction are elevated plasma ACTH and impaired rise of plasma cortisol in response to ACTH challenge. Adrenal antibodies are not present.</p></div><div id="x-ald.Presentations_Seen_in_5_10_of_Affe"><h4>Presentations Seen in ~5%-10% of Affected Males</h4><p><b>Symptom set 4</b> includes headache, increased intracranial pressure, hemiparesis or visual field defect, aphasia or other signs of localized brain disease. Onset is usually between age four and ten years but may occur in adolescence or, rarely, in adults.</p><p><b>Symptom set 5</b> includes progressive behavioral disturbance, dementia, and paralysis in an adult.</p><p><b>Symptom set 6</b> includes progressive incoordination and ataxia in a child or adult.</p><p><b>Symptom set 7</b> includes neurogenic bladder and bowel abnormalities and occasionally impotence without other neurologic or endocrine disturbance in at-risk males who have a positive family history.</p><p><b>Symptom set 8</b> shows no evidence of neurologic or endocrine dysfunction.</p></div><div id="x-ald.Female_Carriers"><h4>Female Carriers</h4><p>More than 20% of female carriers develop mild to moderate spastic paraparesis in middle age or later. Adrenal function is usually normal.</p></div></div><div id="x-ald.GenotypePhenotype_Correlations"><h3>Genotype-Phenotype Correlations</h3><p>The <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> cannot be predicted by VLCFA plasma concentration or by the nature of the <i>ABCD1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, as the same pathogenic variant can be associated with each of the known phenotypes. Mild phenotypes may be associated with large deletions that abolish formation of the <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>, and severe phenotypes occur with <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> pathogenic variants in which abundant immunoreactive protein product is produced [<a class="bk_pop" href="#x-ald.REF.moser.1999.46">Moser &#x00026; Moser 1999</a>, <a class="bk_pop" href="#x-ald.REF.takano.1999.295">Takano et al 1999</a>, <a class="bk_pop" href="#x-ald.REF.pan.2005.114">Pan et al 2005</a>].</p></div><div id="x-ald.Penetrance"><h3>Penetrance</h3><p>The biochemical <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> of elevated plasma concentration of VLCFA has nearly 100% <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a> in males.</p><p>Although the variation in clinical phenotypes is great, neurologic manifestations are present in nearly all males by adulthood.</p></div><div id="x-ald.Nomenclature"><h3>Nomenclature</h3><p>Siemerling-Creuzfeldt disease is the eponym for X-ALD.</p><p>Historically, the eponym Schilder's disease referred to several clinical entities including X-ALD; on occasion, families may have been given this diagnosis. Schilder's disease is still sometimes (incorrectly) used to refer to sudanophilic cerebral sclerosis and certain forms of multiple sclerosis, which may lead to diagnostic confusion.</p></div><div id="x-ald.Prevalence"><h3>Prevalence</h3><p>The prevalence is estimated at between 1:20,000 and 1:50,000. The minimum frequency of hemizygotes (i.e., <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> males) identified in the United States is estimated at 1:21,000 and that of hemizygotes plus heterozygotes (i.e., <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> females) at 1:16,800 [<a class="bk_pop" href="#x-ald.REF.bezman.2001.512">Bezman et al 2001</a>].</p><p>The prevalence appears to be approximately the same in all ethnic groups.</p></div></div><div id="x-ald.Genetically_Related_Allelic_Disord"><h2 id="_x-ald_Genetically_Related_Allelic_Disord_">Genetically Related (Allelic) Disorders</h2><p><b>CADDS</b> (OMIM <a href="http://omim.org/entry/300475" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">300475</a>). Three males with a contiguous <a class="def" href="/books/n/gene/glossary/def-item/deletion-syndrome/">deletion syndrome</a> involving <i>BCAP31</i> and the 5' end of <i>ABCD1</i>, termed CADDS (<i>c</i>ontiguous <i>ABCD1/DXS1357E</i>
<i>d</i>eletion <i>s</i>yndrome), were described by <a class="bk_pop" href="#x-ald.REF.corzo.2002.1520">Corzo et al [2002]</a>. Subsequently, other similarly <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> males have been described [<a class="bk_pop" href="#x-ald.REF.calhoun.2014.2613">Calhoun &#x00026; Raymond 2014</a>, <a class="bk_pop" href="#x-ald.REF.van_de_kamp.2015.141">van de Kamp et al 2015</a>]. The <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> of CADDS is earlier in onset than and distinct from the phenotype resulting from pathogenic variants in <i>ABCD1</i> alone. All affected boys had neonatal cholestasis, hypotonia, and developmental delay. None had craniofacial abnormalities. All died before age one year. The finding that implicated <i>ABCD1</i> in this new syndrome was immunocytochemical analysis of cultured cells that demonstrated morphologically normal peroxisomes lacking the membrane protein encoded by <i>ABCD1</i>. Three of the five mothers were found to be deletion carriers.</p><p>CADDS contrasts with X-ALD, in which the earliest onset of neurologic symptoms is age 2.75 years and liver disease is not observed. Plasma very long chain fatty acid concentrations were elevated in CADDS; however, in contrast to the <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> <a href="/books/n/gene/pbd/">peroxisome biogenesis disorders, Zellweger syndrome spectrum</a>, all other peroxisomal metabolic pathways tested were normal.</p></div><div id="x-ald.Differential_Diagnosis"><h2 id="_x-ald_Differential_Diagnosis_">Differential Diagnosis</h2><p>Conditions that may share clinical features with <a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a> adrenoleukodystrophy (X-ALD) include the following:</p><ul><li class="half_rhythm"><div><b>Symptom set 1 (childhood cerebral form).</b> Attention-deficit disorder; epilepsy and other types of Addison disease; brain tumor; other types of leukodystrophy including <a href="/books/n/gene/mld/">arylsulfatase A deficiency</a> (metachromatic leukodystrophy) and <a href="/books/n/gene/krabbe/">Krabbe disease</a> (globoid cell leukodystrophy); subacute sclerosing encephalitis, multiple sclerosis, Lyme disease, and other dementing disorders including juvenile neuronal ceroid-lipofuscinosis (Batten disease)</div></li><li class="half_rhythm"><div><b>Symptom set 2 (adrenomyeloneuropathy).</b> Multiple sclerosis, progressive spastic paraparesis (see <a href="/books/n/gene/hsp/">Hereditary Spastic Paraplegia Overview</a>), <a href="/books/n/gene/als-overview/">amyotrophic lateral sclerosis</a>, vitamin B<sub>12</sub> deficiency, spinal cord tumor, and cervical spondylosis</div></li><li class="half_rhythm"><div><b>Symptom set 3 (Addison disease only).</b> Allgrove syndrome (achalasia, alacrima, autonomic disturbance, and Addison disease; OMIM <a href="http://omim.org/entry/231550" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">231550</a>). Males with apparently <a class="def" href="/books/n/gene/glossary/def-item/isolated/">isolated</a> primary adrenal insufficiency (i.e., no evidence for other systemic involvement) should be evaluated with plasma VLCFA because X-ALD is the most common genetic cause of Addison disease [<a class="bk_pop" href="#x-ald.REF.aubourg.2003.104">Aubourg &#x00026; Chaussain 2003</a>]. The occurrence of Addison disease in female carriers for X-ALD is rare.</div></li><li class="half_rhythm"><div><b>Symptom set 4.</b> Brain tumor, <a href="/books/n/gene/melas/">MELAS</a>, <a href="/books/n/gene/cadasil/">CADASIL</a></div></li><li class="half_rhythm"><div><b>Symptom set 5.</b> Alzheimer disease (see <a href="/books/n/gene/alzheimer/">Alzheimer Disease Overview</a>), alcoholic or toxic encephalopathy, solvent vapor exposure, psychosis</div></li><li class="half_rhythm"><div><b>Symptom set 6.</b> Olivopontocerebellar degeneration and other progressive ataxias (see <a href="/books/n/gene/ataxias/">Hereditary Ataxia Overview</a>)</div></li><li class="half_rhythm"><div><b>Symptom set 7.</b> Other causes of neurogenic bladder/bowel or impotence</div></li></ul><p>See also <a href="/books/n/gene/leukodys-ov/">Leukodystrophy Overview</a>.</p></div><div id="x-ald.Management"><h2 id="_x-ald_Management_">Management</h2><div id="x-ald.Evaluations_Following_Initial_Diag"><h3>Evaluations Following Initial Diagnosis</h3><p>To establish the extent of disease and needs in an individual diagnosed with <a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a> adrenoleukodystrophy (X-ALD), the following evaluations are recommended if they have not already been completed:</p><ul><li class="half_rhythm"><div>Neurologic examination</div></li><li class="half_rhythm"><div>Brain MRI</div></li><li class="half_rhythm"><div>Adrenal function tests [<a class="bk_pop" href="#x-ald.REF.dubey.2005.528">Dubey et al 2005</a>]</div></li><li class="half_rhythm"><div>Consultation with a clinical geneticist and/or genetic counselor</div></li></ul></div><div id="x-ald.Treatment_of_Manifestations"><h3>Treatment of Manifestations</h3><p>When adrenal insufficiency is identified in an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> male, corticosteroid replacement therapy is essential and can be lifesaving. (Corticosteroid replacement therapy has no effect on nervous system involvement.)</p><p>Affected boys with cerebral disease benefit from the general supportive care of parents, as well as psychological and educational support.</p><p>Physical therapy, management of urologic complications, and family and vocational counseling are of value for men with adrenomyeloneuropathy, many of whom maintain successful personal and professional lives [<a class="bk_pop" href="#x-ald.REF.silveri.2004.2651">Silveri et al 2004</a>].</p></div><div id="x-ald.Prevention_of_Primary_Manifestatio"><h3>Prevention of Primary Manifestations</h3><p>Hematopoietic stem cell transplantation (HSCT) is an option for boys and adolescents in early stages of symptom set 1 who have evidence of brain involvement on MRI.</p><p>In X-ALD, HSCT has been associated with a 20% risk for morbidity and mortality and is recommended only for individuals with evidence of brain involvement by MRI and minimal neuropsychologic findings (performance IQ &#x0003e;80) with a normal clinical neurologic examination.</p><p>HSCT is not recommended for individuals with severe neurologic and neuropsychologic dysfunction (i.e., performance IQ &#x0003c;80) [<a class="bk_pop" href="#x-ald.REF.shapiro.2000.713">Shapiro et al 2000</a>, <a class="bk_pop" href="#x-ald.REF.baumann.2003.6">Baumann et al 2003</a>, <a class="bk_pop" href="#x-ald.REF.loes.2003.369">Loes et al 2003</a>, <a class="bk_pop" href="#x-ald.REF.peters.2004.881">Peters et al 2004</a>, <a class="bk_pop" href="#x-ald.REF.mahmood.2005.55">Mahmood et al 2005</a>, <a class="bk_pop" href="#x-ald.REF.resnick.2005.840">Resnick et al 2005</a>].</p></div><div id="x-ald.Surveillance"><h3>Surveillance</h3><p>Adrenal function should be reevaluated periodically in males with X-ALD whose initial evaluation revealed normal adrenal cortical function [<a class="bk_pop" href="#x-ald.REF.dubey.2005.528">Dubey et al 2005</a>]. With the institution of <a class="def" href="/books/n/gene/glossary/def-item/newborn-screening/">newborn screening</a>, specific professional guidelines are being developed, but it is suggested that this be at least every six months.</p><p>Males with X-ALD should undergo brain MRI. It is presently recommended that this should start at age 12 months and be repeated yearly till age three. From age three to ten years, MRI should be performed every six months to monitor for early evidence of childhood cerebral disease [<a class="bk_pop" href="#x-ald.REF.peters.2004.881">Peters et al 2004</a>] because MRI abnormalities occur well in advance of clinical disease [<a class="bk_pop" href="#x-ald.REF.loes.2003.369">Loes et al 2003</a>]. Evidence clearly shows that HSCT has the best outcome when performed on an asymptomatic individual [<a class="bk_pop" href="#x-ald.REF.shapiro.2000.713">Shapiro et al 2000</a>, <a class="bk_pop" href="#x-ald.REF.peters.2004.881">Peters et al 2004</a>, <a class="bk_pop" href="#x-ald.REF.mahmood.2007.687">Mahmood et al 2007</a>]. Beyond age ten years the frequency of MRI should be yearly because of the development of cerebral changes in some males even in adulthood.</p></div><div id="x-ald.Evaluation_of_Relatives_at_Risk"><h3>Evaluation of Relatives at Risk</h3><p>It is appropriate to evaluate the older and younger at-risk relatives of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual in order to identify as early as possible those who would benefit from timely treatment of adrenal insufficiency before life-threatening complications occur [<a class="bk_pop" href="#x-ald.REF.mahmood.2005.55">Mahmood et al 2005</a>]. Such testing can also allow for correct diagnosis of early (and often nonspecific) neurologic, behavioral, and/or cognitive signs and symptoms.</p><p>If born in the United States, males <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> with X-ALD may be diagnosed by universal <a class="def" href="/books/n/gene/glossary/def-item/newborn-screening/">newborn screening</a> soon after birth. If newborn screening data are not available for at-risk sibs, several diagnostic approaches can be considered.</p><ul><li class="half_rhythm"><div>If the <i>ABCD1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in the family is known, <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> can be used to clarify the genetic status of at-risk relatives.</div></li><li class="half_rhythm"><div>If the <i>ABCD1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in the family is not known, very long chain fatty acid analysis may be used with the limitations previously discussed to clarify the disease status of at-risk relatives.</div></li></ul><p>See <a href="#x-ald.Related_Genetic_Counseling_Issues">Genetic Counseling</a> for issues related to testing of at-risk relatives for <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> purposes.</p></div><div id="x-ald.Therapies_Under_Investigation"><h3>Therapies Under Investigation</h3><p>In a single-arm study of presymptomatic boys with a normal MRI, reduction of hexacosanoic acid (C26:0) by Lorenzo's oil was associated with a reduced risk of developing MRI abnormalities and, therefore, childhood cerebral disease. The authors emphasized that the effectiveness of therapy depended on reduction of C26:0 and that the amount of reduction correlated with lowered risk. Despite this reduction, some individuals still developed childhood cerebral disease. It is emphasized that the study was an open trial without a placebo group; thus, the results should be interpreted with some caution. The use of Lorenzo's oil remains an investigational therapy [<a class="bk_pop" href="#x-ald.REF.moser.2005.1073">Moser et al 2005</a>].</p><p>A trial of <i>ex vivo</i> <a class="def" href="/books/n/gene/glossary/def-item/gene-therapy/">gene therapy</a> is ongoing [<a class="bk_pop" href="#x-ald.REF.eichler.2017.1630">Eichler et al 2017</a>]. This multicenter trial is using transfected hematopoietic stem cells to compare the efficacy of this approach to traditional allogeneic HSCT. Based on recent preliminary results the authors report that Lenti-D gene therapy may be a safe and effective alternative to allogeneic stem-cell transplantation in boys with early-stage cerebral disease.</p><p>Search <a href="http://clinicaltrials.gov/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ClinicalTrials.gov</a> in the US and <a href="http://www.clinicaltrialsregister.eu/ctr-search/search" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">EU Clinical Trials Register</a> in Europe for information on clinical studies for a wide range of diseases and conditions.</p></div></div><div id="x-ald.Genetic_Counseling"><h2 id="_x-ald_Genetic_Counseling_">Genetic Counseling</h2><p>
<i>Genetic counseling is the process of providing individuals and families with
information on the nature, inheritance, and implications of genetic disorders to help them
make informed medical and personal decisions. The following section deals with genetic
risk assessment and the use of family history and genetic testing to clarify genetic
status for family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with a genetics
professional</i>. &#x02014;ED.</p><div id="x-ald.Mode_of_Inheritance"><h3>Mode of Inheritance</h3><p><a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a> adrenoleukodystrophy (X-ALD) is inherited in an X-linked manner.</p></div><div id="x-ald.Risk_to_Family_Members"><h3>Risk to Family Members</h3><p><b>Parents of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>Approximately 95% of probands inherit an <i>ABCD1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> from one parent.</div></li><li class="half_rhythm"><div>At least 4.1% of individuals with X-ALD have a <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> [<a class="bk_pop" href="#x-ald.REF.wang.2011.160">Wang et al 2011</a>].</div></li><li class="half_rhythm"><div>Recommendations for the evaluation of parents of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>:</div><ul><li class="half_rhythm"><div>If an <i>ABCD1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> has been identified in an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> family member, <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> can be used for the evaluation of parents; <i>ABCD1</i> molecular genetic testing is the preferred method for the evaluation of mothers of affected males.</div></li><li class="half_rhythm"><div>Fathers of newly identified <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> females may be evaluated by VLCFA testing.</div></li></ul></li><li class="half_rhythm"><div>In a family with more than one <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual, the mother of an affected male is an <a class="def" href="/books/n/gene/glossary/def-item/obligate-heterozygote/">obligate heterozygote</a> (<a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a>). Note: If a woman has more than one affected child and no other affected relatives and if the <i>ABCD1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> cannot be detected in her leukocyte DNA, she most likely has <a class="def" href="/books/n/gene/glossary/def-item/germline-mosaicism/">germline mosaicism</a> (evidence of germline or somatic/germline mosaicism is present in &#x0003c;1% of parents).</div></li></ul><p><b>Sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>The risk to sibs depends on the genetic status of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>'s parents:</div><ul><li class="half_rhythm"><div>If the mother of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> is <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> for an <i>ABCD1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, the chance of transmitting the pathogenic variant in each pregnancy is 50%.</div></li><li class="half_rhythm"><div>If the father of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> is <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> (i.e., <a class="def" href="/books/n/gene/glossary/def-item/hemizygous/">hemizygous</a> for an <i>ABCD1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>), the pathogenic variant will be transmitted to all of his female offspring and none of his male offspring.</div></li></ul></li><li class="half_rhythm"><div>Male sibs who inherit the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> will be <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>; female sibs who inherit it will be <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> and will usually not be seriously affected.</div></li><li class="half_rhythm"><div>If the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> represents a <a class="def" href="/books/n/gene/glossary/def-item/simplex/">simplex</a> case (i.e., a single occurrence in a family) and if the <i>ABCD1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> cannot be detected in the leukocyte DNA of either parent, the <a class="def" href="/books/n/gene/glossary/def-item/recurrence-risk/">recurrence risk</a> to sibs is slightly greater than that of the general population because of the possibility of parental <a class="def" href="/books/n/gene/glossary/def-item/germline-mosaicism/">germline mosaicism</a> [<a class="bk_pop" href="#x-ald.REF.wang.2011.160">Wang et al 2011</a>].</div></li></ul><p><b>Offspring of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>Affected males transmit the <i>ABCD1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> to all of their daughters (who will be heterozygotes and will usually not be seriously <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>) and none of their sons.</div></li><li class="half_rhythm"><div>Heterozygous females have a 50% chance of transmitting the <i>ABCD1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in each pregnancy. Males who inherit the pathogenic variant will be <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>; females who inherit the pathogenic variant will be heterozygotes and will usually not be seriously affected.</div></li><li class="half_rhythm"><div>Note: Widely varying phenotypes often coexist in the same family. Thus, a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> who has experienced a relatively mild <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> may have offspring who display the severe phenotype.</div></li></ul><p><b>Other family members.</b> Depending on their gender, family relationship, and the genetic status of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>'s parents, the proband's aunts and uncles and their offspring may be at risk of being carriers or of being <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> (see <a href="#x-ald.Related_Genetic_Counseling_Issues">Related Genetic Counseling Issues</a>).</p></div><div id="x-ald.Heterozygote_Carrier_Detection"><h3>Heterozygote (Carrier) Detection</h3><p>Molecular genetic testing of at-risk female relatives to determine their genetic status is most informative if the <i>ABCD1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> has been identified in the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</p><ul><li class="half_rhythm"><div>Females who are <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> for this <a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a> disorder will usually not be seriously <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>.</div></li><li class="half_rhythm"><div>Identification of female heterozygotes requires either (a) prior identification of the <i>ABCD1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in the family or, (b) if an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> male is not available for testing, <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> first by <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a>, and if no pathogenic variant is identified, by <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>.</div></li></ul><p>Note: Very long chain fatty acid analysis is not recommended as a screening method for females known to be at risk (see <a href="#x-ald.Establishing_the_Diagnosis">Establishing the Diagnosis</a>).</p></div><div id="x-ald.Related_Genetic_Counseling_Issues"><h3>Related Genetic Counseling Issues</h3><p><b>At-risk, asymptomatic, or symptomatic but undiagnosed family members.</b> It is appropriate for at-risk males in a family to be identified and to be informed of their risk for X-ALD, while respecting principles of patient confidentiality. Identification of males with X-ALD through measurement of plasma concentration of VLCFA &#x02013; or <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> if the <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> <i>ABCD1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is known &#x02013; before symptoms occur or early in the course of the disease can allow for diagnosis and management of adrenal insufficiency before life-threatening complications occur. Such testing can also allow for correct diagnosis of early (and often nonspecific) neurologic, behavioral, and/or cognitive signs and symptoms. (See Management, <a href="#x-ald.Evaluation_of_Relatives_at_Risk">Evaluation of Relatives at Risk</a>.)</p><p><b>Evaluation of at-risk family members</b> is important for management and <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> but is often incompletely implemented. Several factors may contribute to insufficient evaluation:</p><ul><li class="half_rhythm"><div>Establishing the diagnosis in an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual with severe disability may be devastating to a family. Immediate concerns may overshadow the timely testing of family members.</div></li><li class="half_rhythm"><div>Third-party payors may not cover the cost of testing at-risk family members.</div></li><li class="half_rhythm"><div>Some at-risk family members may choose not to be tested because they fear that a positive result could impair their ability to obtain or retain medical insurance coverage.</div></li><li class="half_rhythm"><div>Individuals may have incomplete knowledge about at-risk family members and may not wish to inform them about the risk.</div></li></ul><p><b>Family planning</b></p><ul><li class="half_rhythm"><div>The optimal time for determination of genetic risk, clarification of <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> status, and discussion of the availability of prenatal testing is before pregnancy.</div></li><li class="half_rhythm"><div>It is appropriate to offer <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> (including discussion of potential risks to offspring and reproductive options) to young adults who are <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>, are carriers, or are at risk of being carriers.</div></li></ul><p><b>DNA banking</b> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals.</p></div><div id="x-ald.Prenatal_Testing_and_Preimplantati"><h3>Prenatal Testing and Preimplantation Genetic Diagnosis</h3><p><b>Molecular genetic testing</b></p><ul><li class="half_rhythm"><div>Once the <i>ABCD1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> has been identified in an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> family member, molecular genetic prenatal testing for a pregnancy at increased risk is possible.</div></li><li class="half_rhythm"><div>Preimplantation genetic diagnosis may be an option for some families in whom the <i>ABCD1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> has been identified or for those who would choose to implant only female embryos to avoid the possibility of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> male.</div></li></ul><p><b>Biochemical testing.</b> If <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> is not available, very long chain fatty acids can be measured in cultured amniocytes or cultured chorionic villus cells [<a class="bk_pop" href="#x-ald.REF.wanders.1998.285">Wanders et al 1998</a>, <a class="bk_pop" href="#x-ald.REF.moser.1999.100">Moser et al 1999</a>]. Prenatal diagnosis using biochemical testing requires prior biochemical confirmation of the diagnosis in the family.</p><p>Note: (1) False negative test results using biochemical testing have been reported but may have been related to technical factors. (2) Very long chain fatty acid measurement should be performed only by a laboratory with significant experience.</p></div></div><div id="x-ald.Resources"><h2 id="_x-ald_Resources_">Resources</h2><p>
<i>GeneReviews staff has selected the following disease-specific and/or umbrella
support organizations and/or registries for the benefit of individuals with this disorder
and their families. GeneReviews is not responsible for the information provided by other
organizations. For information on selection criteria, click <a href="/books/n/gene/app4/">here</a>.</i></p><ul><li class="half_rhythm"><div><b>Adrenoleukodystrophy Foundation</b></div><div>241 Camden Street</div><div>Slidell LA 70461</div><div><b>Phone:</b> 985-718-4728</div><div><b>Email:</b> information@adlfoundation.org</div><div><a href="http://www.aldfoundation.org" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.aldfoundation.org</a></div></li><li class="half_rhythm"><div><b>ALD Connect</b></div><div><b>Phone:</b> 617-643-4218</div><div><b>Email:</b> admin@aldconnect.org</div><div><a href="http://www.x-ald.nl/clinical-diagnosis/the-ald-connect-patient-portal/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.x-ald.nl</a></div></li><li class="half_rhythm"><div><b>Leukodystrophy Australia</b></div><div>P O Box 2550</div><div>Mount Waverley Victoria 3149</div><div>Australia</div><div><b>Phone:</b> 1800-141-400 (toll free)</div><div><b>Email:</b> info@leuko.org.au</div><div><a href="http://www.leuko.org.au/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.leuko.org.au</a></div></li><li class="half_rhythm"><div><b>National Institute of Neurological Disorders and Stroke (NINDS)</b></div><div>PO Box 5801</div><div>Bethesda MD 20824</div><div><b>Phone:</b> 800-352-9424 (toll-free); 301-496-5751; 301-468-5981 (TTY)</div><div><a href="https://www.ninds.nih.gov/Disorders/All-Disorders/Adrenoleukodystrophy-Information-Page" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Adrenoleukodystrophy Information Page</a></div></li><li class="half_rhythm"><div><b>NCBI Genes and Disease</b></div><div><a href="/books/NBK22230/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Adrenoleukodystrophy</a></div></li><li class="half_rhythm"><div><b>Myelin Project</b></div><div>P.O. Box 39</div><div>Pacific Palisades CA 90272</div><div><b>Phone:</b> 800-869-3546 (toll-free)</div><div><b>Fax:</b> 310-230-4298</div><div><b>Email:</b> margaret.weis@myelin.org</div><div><a href="http://www.myelin.org" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.myelin.org</a></div></li><li class="half_rhythm"><div><b>United Leukodystrophy Foundation (ULF)</b></div><div>224 North Second Street</div><div>Suite 2</div><div>DeKalb IL 60115</div><div><b>Phone:</b> 800-728-5483 (toll-free); 815-748-3211</div><div><b>Fax:</b> 815-748-0844</div><div><b>Email:</b> office@ulf.org</div><div><a href="http://www.ulf.org" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.ulf.org</a></div></li><li class="half_rhythm"><div><b>Myelin Disorders Bioregistry Project</b></div><div><b>Email:</b> myelindisorders@cnmc.org</div><div><a href="https://www.chop.edu/research/myelin-disorders-biorepository-project" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Myelin Disorders Bioregistry Project</a></div></li></ul></div><div id="x-ald.Molecular_Genetics"><h2 id="_x-ald_Molecular_Genetics_">Molecular Genetics</h2><p><i>Information in the Molecular Genetics and OMIM tables may differ from that elsewhere in the GeneReview: tables may contain more recent information. &#x02014;</i>ED.</p><div id="x-ald.molgen.TA" class="table"><h3><span class="label">Table A.</span></h3><div class="caption"><p>X-Linked Adrenoleukodystrophy: Genes and Databases</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1315/table/x-ald.molgen.TA/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__x-ald.molgen.TA_lrgtbl__"><table class="no_bottom_margin"><tbody><tr><th id="hd_b_x-ald.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Gene</th><th id="hd_b_x-ald.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">Chromosome Locus</th><th id="hd_b_x-ald.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">Protein</th><th id="hd_b_x-ald.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">Locus-Specific Databases</th><th id="hd_b_x-ald.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">HGMD</th><th id="hd_b_x-ald.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">ClinVar</th></tr><tr><td headers="hd_b_x-ald.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/215" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>ABCD1</i></a></td><td headers="hd_b_x-ald.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=215" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Xq28</a></td><td headers="hd_b_x-ald.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/P33897" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ATP-binding cassette sub-family D member 1</a></td><td headers="hd_b_x-ald.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.LOVD.nl/ABCD1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ABCD1 @ LOVD</a><br /><a href="http://reseq.biosciencedbc.jp/resequence/GeneDetail.do?targetId=4&#x00026;geneId=EG215" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ALD mutation database (ABCD1)</a><br /><a href="http://www.x-ald.nl" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">X-linked Adrenoleukodystrophy Database (ABCD1)</a></td><td headers="hd_b_x-ald.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=ABCD1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ABCD1</a></td><td headers="hd_b_x-ald.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=ABCD1[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ABCD1</a></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div id="x-ald.TFA.1"><p class="no_margin">Data are compiled from the following standard references: <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> from
<a href="http://www.genenames.org/index.html" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">HGNC</a>;
<a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> from
<a href="http://www.omim.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">OMIM</a>;
protein from <a href="http://www.uniprot.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">UniProt</a>.
For a description of databases (Locus Specific, HGMD, ClinVar) to which links are provided, click
<a href="/books/n/gene/app1/">here</a>.</p></div></dd></dl></div></div></div><div id="x-ald.molgen.TB" class="table"><h3><span class="label">Table B.</span></h3><div class="caption"><p>OMIM Entries for X-Linked Adrenoleukodystrophy (<a href="/omim/300100,300371" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">View All in OMIM</a>) </p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1315/table/x-ald.molgen.TB/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__x-ald.molgen.TB_lrgtbl__"><table><tbody><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/300100" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">300100</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">ADRENOLEUKODYSTROPHY; ALD</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/300371" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">300371</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">ATP-BINDING CASSETTE, SUBFAMILY D, MEMBER 1; ABCD1</td></tr></tbody></table></div></div><p><b>Gene structure.</b>
<i>ABCD1</i> contains ten exons and spans 20 kb of <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> DNA. The 3,616-bp transcript has 2,235 bp of coding sequence. Exon 1 is the largest, encompassing 900 bp. For a detailed summary of <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> and protein information, see <a href="/books/NBK1315/#x-ald.molgen.TA">Table A</a>, <b>Gene</b>.</p><p><b>Pathogenic variants.</b> The comprehensive <a href="http://www.x-ald.nl/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">X-linked adrenoleukodystrophy database</a> lists 770 non-recurrent pathogenic and likely pathogenic variants, as well as rare variants of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a> identified in <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> males or obligate heterozygotes [<a class="bk_pop" href="#x-ald.REF.kemp.2001.499">Kemp et al 2001</a>]. Non-recurrent pathogenic variants account for approximately half of the disease-causing variants reported, which include <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> pathogenic variants (~61%), frameshifts (~17%), <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a> pathogenic variants (~10%), <a class="def" href="/books/n/gene/glossary/def-item/in-frame/">in-frame</a> deletions/insertions (~4%), and large deletions (~3%).</p><p>The most common recurring <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is <a class="figpopup" href="/books/NBK1315/table/x-ald.T.selected_abcd1_pathogenic_varian/?report=objectonly" target="object" rid-figpopup="figxaldTselectedabcd1pathogenicvarian" rid-ob="figobxaldTselectedabcd1pathogenicvarian">c.1415_1416delAG</a> in <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 5. This variant has been reported in 7% of families and has been observed with approximately the same frequency in all ethnic groups.</p><p>Missense variants have been found in all parts of the <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> but are most common in the membrane <a class="def" href="/books/n/gene/glossary/def-item/domain/">domain</a> or the ATP-binding domain, emphasizing the importance of these two domains for the function of ALDP. In the series of 423 hemizygotes and obligate heterozygotes from the authors' experience, 62% of the detected sequence variants predicted <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> variants. Two thirds were previously reported in association with X-ALD. Furthermore, 29% of all patients had one of 15 pathogenic variants, including c.1415_1416delAG [SJ Steinberg, personal observation].</p><div id="x-ald.T.selected_abcd1_pathogenic_varian" class="table"><h3><span class="label">Table 3. </span></h3><div class="caption"><p>Selected <i>ABCD1</i> Pathogenic Variants</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1315/table/x-ald.T.selected_abcd1_pathogenic_varian/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__x-ald.T.selected_abcd1_pathogenic_varian_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_x-ald.T.selected_abcd1_pathogenic_varian_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">DNA Nucleotide Change<br />(Alias&#x000a0;<sup>1</sup>)</th><th id="hd_h_x-ald.T.selected_abcd1_pathogenic_varian_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Predicted Protein Change<br />(Alias&#x000a0;<sup>1,&#x000a0;2</sup>)</th><th id="hd_h_x-ald.T.selected_abcd1_pathogenic_varian_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Reference Sequences</th></tr></thead><tbody><tr><td headers="hd_h_x-ald.T.selected_abcd1_pathogenic_varian_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.1415_1416delAG<br />(c.1801_1802delAG)</td><td headers="hd_h_x-ald.T.selected_abcd1_pathogenic_varian_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Gln472ArgfsTer83<br />(fsGlu471)</td><td headers="hd_h_x-ald.T.selected_abcd1_pathogenic_varian_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/entrez/viewer.fcgi?val=NM_000033.2" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_000033<wbr style="display:inline-block"></wbr>​.2</a><br /><a href="/entrez/viewer.fcgi?val=NP_000024.2" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NP_000024<wbr style="display:inline-block"></wbr>​.2</a></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">Variants listed in the table have been provided by the authors. <i>GeneReviews</i> staff have not independently verified the classification of variants.</p></div></dd><dt></dt><dd><div><p class="no_margin"><i>GeneReviews</i> follows the standard naming conventions of the Human Genome Variation Society (<a href="http://varnomen.hgvs.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">varnomen<wbr style="display:inline-block"></wbr>​.hgvs.org</a>). See <a href="/books/n/gene/app3/">Quick Reference</a> for an explanation of nomenclature.</p></div></dd><dt>1. </dt><dd><div id="x-ald.TF.3.1"><p class="no_margin">Variant designation that does not conform to current naming conventions</p></div></dd><dt>2. </dt><dd><div id="x-ald.TF.3.2"><p class="no_margin">Nomenclature used in the literature</p></div></dd></dl></div></div></div><p><b>Normal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> The adrenoleukodystrophy protein (ALDP) contains 745 amino acids and is located in the peroxisomal membrane. It is a member of the ATP-binding cassette (ABC) protein transporter family. It is a characteristic feature of the family of ABC transporters that they function as dimers of two related halves. ALDP represents only one of these halves and is referred to as a half-transporter. Binding of two half-transporters creates a functional transporter whereby the two membrane domains form a channel through which the substrate is transported. Each of the ABC half-transporters contains a hydrophobic membrane <a class="def" href="/books/n/gene/glossary/def-item/domain/">domain</a> with six membrane-spanning segments. The combination of the individual components may determine the specificity of the transporter. ALDP has been shown to be able to form a homodimer. ALDP homodimers are believed to be responsible for the transport of very long chain fatty acids across the peroxisome membrane from the cytosol [<a class="bk_pop" href="#x-ald.REF.van_roermund.2008.4201">van Roermund et al 2008</a>]</p><p><b>Abnormal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> The gene product is absent in 70% of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals and, for reasons that are not well understood, may be absent even in individuals who have <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> pathogenic variants. The principal biochemical abnormality is the accumulation of saturated, very long chain fatty acids, particularly hexacosanoic (C26:0) and tetracosanoic (C24:0) fatty acids, as a result of the impaired capacity to degrade these substances, a function that normally takes place in the peroxisome. It is not yet known how the defect in ALDP leads to the accumulation of very long chain fatty acids, but the protein appears to be required for the transport of these fatty acids into the peroxisome.</p></div><div id="x-ald.References"><h2 id="_x-ald_References_">References</h2><div id="x-ald.Literature_Cited"><h3>Literature Cited</h3><ul class="simple-list"><li class="half_rhythm"><div class="bk_ref" id="x-ald.REF.aubourg.2003.104">Aubourg P, Chaussain JL. Adrenoleukodystrophy: the most frequent genetic cause of Addison's disease. <span><span class="ref-journal">Horm Res. </span>2003;<span class="ref-vol">59</span> Suppl 1:104–5.</span> [<a href="/pubmed/12638520" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12638520</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="x-ald.REF.baumann.2003.6">Baumann M, Korenke GC, Weddige-Diedrichs A, Wilichowski E, Hunneman DH, Wilken B, Brockmann K, Klingebiel T, Niethammer D, K&#x000fc;hl J, Ebell W, Hanefeld F. Haematopoietic stem cell transplantation in 12 patients with cerebral X-linked adrenoleukodystrophy. <span><span class="ref-journal">Eur J Pediatr. </span>2003;<span class="ref-vol">162</span>:6–14.</span> [<a href="/pubmed/12486501" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12486501</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="x-ald.REF.bezman.2001.512">Bezman L, Moser AB, Raymond GV, Rinaldo P, Watkins PA, Smith KD, Kass NE, Moser HW. Adrenoleukodystrophy: incidence, new mutation rate, and results of extended family screening. <span><span class="ref-journal">Ann Neurol. </span>2001;<span class="ref-vol">49</span>:512–7.</span> [<a href="/pubmed/11310629" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11310629</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="x-ald.REF.calhoun.2014.2613">Calhoun AR, Raymond GV. Distal Xq28 microdeletions: clarification of the spectrum of contiguous gene deletions involving ABCD1, BCAP31, and SLC6A8 with a new case and review of the literature. <span><span class="ref-journal">Am J Med Genet A. </span>2014;<span class="ref-vol">164A</span>:2613–7.</span> [<a href="/pubmed/25044748" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25044748</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="x-ald.REF.corzo.2002.1520">Corzo D, Gibson W, Johnson K, Mitchell G, LePage G, Cox GF, Casey R, Zeiss C, Tyson H, Cutting GR, Raymond GV, Smith KD, Watkins PA, Moser AB, Moser HW, Steinberg SJ. Contiguous deletion of the X-linked adrenoleukodystrophy gene (ABCD1) and DXS1357E: a novel neonatal phenotype similar to peroxisomal biogenesis disorders. <span><span class="ref-journal">Am J Hum Genet. </span>2002;<span class="ref-vol">70</span>:1520–31.</span> [<a href="/pmc/articles/PMC419992/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC419992</span></a>] [<a href="/pubmed/11992258" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11992258</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="x-ald.REF.dubey.2005.528">Dubey P, Raymond GV, Moser AB, Kharkar S, Bezman L, Moser HW. Adrenal insufficiency in asymptomatic adrenoleukodystrophy patients identified by very long-chain fatty acid screening. <span><span class="ref-journal">J Pediatr. </span>2005;<span class="ref-vol">146</span>:528–32.</span> [<a href="/pubmed/15812458" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15812458</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="x-ald.REF.eichler.2017.1630">Eichler F, Duncan C, Musolino PL, Orchard PJ, De Oliveira S, Thrasher AJ, Armant M, Dansereau C, Lund TC, Miller WP, Raymond GV, Sankar R, Shah AJ, Sevin C, Gaspar HB, Gissen P, Amartino H, Bratkovic D, Smith NJC, Paker AM, Shamir E, O'Meara T, Davidson D, Aubourg P, Williams DA. Hematopoietic stem-cell gene therapy for cerebral adrenoleukodystrophy. <span><span class="ref-journal">N Engl J Med. </span>2017;<span class="ref-vol">377</span>:1630–8.</span> [<a href="/pmc/articles/PMC5708849/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5708849</span></a>] [<a href="/pubmed/28976817" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28976817</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="x-ald.REF.hershkovitz.2002.234">Hershkovitz E, Narkis G, Shorer Z, Moser AB, Watkins PA, Moser HW, Manor E. Cerebral X-linked adrenoleukodystrophy in a girl with Xq27-Ter deletion. <span><span class="ref-journal">Ann Neurol. </span>2002;<span class="ref-vol">52</span>:234–7.</span> [<a href="/pubmed/12210797" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12210797</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="x-ald.REF.kemp.2001.499">Kemp S, Pujol A, Waterham HR, van Geel BM, Boehm CD, Raymond GV, Cutting GR, Wanders RJ, Moser HW. ABCD1 mutations and the X-linked adrenoleukodystrophy mutation database: role in diagnosis and clinical correlations. <span><span class="ref-journal">Hum Mutat. </span>2001;<span class="ref-vol">18</span>:499–515.</span> [<a href="/pubmed/11748843" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11748843</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="x-ald.REF.loes.2003.369">Loes DJ, Fatemi A, Melhem ER, Gupte N, Bezman L, Moser HW, Raymond GV. Analysis of MRI patterns aids prediction of progression in X-linked adrenoleukodystrophy. <span><span class="ref-journal">Neurology. </span>2003;<span class="ref-vol">61</span>:369–74.</span> [<a href="/pubmed/12913200" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12913200</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="x-ald.REF.mahmood.2005.55">Mahmood A, Dubey P, Moser HW, Moser A. X-linked adrenoleukodystrophy: therapeutic approaches to distinct phenotypes. <span><span class="ref-journal">Pediatr Transplant. </span>2005;<span class="ref-vol">9</span>:55–62.</span> [<a href="/pubmed/16305618" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16305618</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="x-ald.REF.mahmood.2007.687">Mahmood A, Raymond GV, Dubey P, Peters C, Moser HW. Survival analysis of haematopoietic cell transplantation for childhood cerebral X-linked adrenoleukodystrophy: a comparison study. <span><span class="ref-journal">Lancet Neurol. </span>2007;<span class="ref-vol">6</span>:687–92.</span> [<a href="/pubmed/17618834" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17618834</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="x-ald.REF.moser.1999.100">Moser AB, Kreiter N, Bezman L, Lu S, Raymond GV, Naidu S, Moser HW. Plasma very long chain fatty acids in 3,000 peroxisome disease patients and 29,000 controls. <span><span class="ref-journal">Ann Neurol. </span>1999;<span class="ref-vol">45</span>:100–10.</span> [<a href="/pubmed/9894883" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9894883</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="x-ald.REF.moser.1999.46">Moser AB, Moser HW. The prenatal diagnosis of X-linked adrenoleukodystrophy. <span><span class="ref-journal">Prenat Diagn. </span>1999;<span class="ref-vol">19</span>:46–8.</span> [<a href="/pubmed/10073906" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10073906</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="x-ald.REF.moser.2005.1073">Moser HW, Raymond GV, Lu SE, Muenz LR, Moser AB, Xu J, Jones RO, Loes DJ, Melhem ER, Dubey P, Bezman L, Brereton NH, Odone A. Follow-up of 89 asymptomatic patients with adrenoleukodystrophy treated with Lorenzo's oil. <span><span class="ref-journal">Arch Neurol. </span>2005;<span class="ref-vol">62</span>:1073–80.</span> [<a href="/pubmed/16009761" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16009761</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="x-ald.REF.moser.2001">Moser HW, Smith KD, Watkins PA, Powers J, Moser AB. X-linked adrenoleukodystrophy. In: Scriver CR, Beaudet AL, Valle D, Sly WS, eds. <em>The Metabolic &#x00026; Molecular Basis of Inherited Disease</em>. 8 ed. New York, NY: McGraw-Hill; 2001:3257-302.</div></li><li class="half_rhythm"><div class="bk_ref" id="x-ald.REF.pan.2005.114">Pan H, Xiong H, Wu Y, Zhang YH, Bao XH, Jiang YW, Wu XR. ABCD1 gene mutations in Chinese patients with X-linked adrenoleukodystrophy. <span><span class="ref-journal">Pediatr Neurol. </span>2005;<span class="ref-vol">33</span>:114–20.</span> [<a href="/pubmed/16087056" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16087056</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="x-ald.REF.peters.2004.881">Peters C, Charnas LR, Tan Y, Ziegler RS, Shapiro EG, DeFor T, Grewal SS, Orchard PJ, Abel SL, Goldman AI, Ramsay NK, Dusenbery KE, Loes DJ, Lockman LA, Kato S, Aubourg PR, Moser HW, Krivit W. Cerebral X-linked adrenoleukodystrophy: the international hematopoietic cell transplantation experience from 1982 to 1999. <span><span class="ref-journal">Blood. </span>2004;<span class="ref-vol">104</span>:881–8.</span> [<a href="/pubmed/15073029" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15073029</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="x-ald.REF.resnick.2005.840">Resnick IB, Abdul Hai A, Shapira MY, Bitan M, Hershkovitz E, Schwartz A, Ben-Harush M, Or R, Slavin S, Kapelushnik J. Treatment of X-linked childhood cerebral adrenoleukodystrophy by the use of an allogeneic stem cell transplantation with reduced intensity conditioning regimen. <span><span class="ref-journal">Clin Transplant. </span>2005;<span class="ref-vol">19</span>:840–7.</span> [<a href="/pubmed/16313334" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16313334</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="x-ald.REF.schackmann.2016.123">Schackmann MJ, Ofman R, van Geel BM, Dijkstra IM, van Engelen K, Wanders RJ, Engelen M, Kemp S. Pathogenicity of novel ABCD1 variants: The need for biochemical testing in the era of advanced genetics. <span><span class="ref-journal">Mol Genet Metab. </span>2016;<span class="ref-vol">118</span>:123–7.</span> [<a href="/pubmed/27067449" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27067449</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="x-ald.REF.shapiro.2000.713">Shapiro E, Krivit W, Lockman L, Jambaque I, Peters C, Cowan M, Harris R, Blanche S, Bordigoni P, Loes D, Ziegler R, Crittenden M, Ris D, Berg B, Cox C, Moser H, Fischer A, Aubourg P. Long-term effect of bone-marrow transplantation for childhood-onset cerebral X-linked adrenoleukodystrophy. <span><span class="ref-journal">Lancet. </span>2000;<span class="ref-vol">356</span>:713–8.</span> [<a href="/pubmed/11085690" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11085690</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="x-ald.REF.silveri.2004.2651">Silveri M, De Gennaro M, Gatti C, Bizzarri C, Mosiello G, Cappa M. Voiding dysfunction in x-linked adrenoleukodystrophy: symptom score and urodynamic findings. <span><span class="ref-journal">J Urol. </span>2004;<span class="ref-vol">171</span>:2651–3.</span> [<a href="/pubmed/15118443" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15118443</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="x-ald.REF.steinberg.2008">Steinberg S, Jones R, Tiffany C, Moser A. Investigational methods for peroxisomal disorders. <span><span class="ref-journal">Curr Protoc Hum Genet. </span>2008.</span>  [<a href="/pubmed/18633975" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18633975</span></a>] [<a href="http://dx.crossref.org/10.1002/0471142905.hg1706s58" ref="pagearea=cite-ref&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">CrossRef</a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="x-ald.REF.takano.1999.295">Takano H, Koike R, Onodera O, Sasaki R, Tsuji S. Mutational analysis and genotype-phenotype correlation of 29 unrelated Japanese patients with X-linked adrenoleukodystrophy. <span><span class="ref-journal">Arch Neurol. </span>1999;<span class="ref-vol">56</span>:295–300.</span> [<a href="/pubmed/10190819" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10190819</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="x-ald.REF.van_de_kamp.2015.141">van de Kamp JM, Errami A, Howidi M, Anselm I, Winter S, Phalin-Roque J, Osaka H, van Dooren SJ, Mancini GM, Steinberg SJ, Salomons GS. Genotype-phenotype correlation of contiguous gene deletions of SLC6A8, BCAP31 and ABCD1. <span><span class="ref-journal">Clin Genet. </span>2015;<span class="ref-vol">87</span>:141–7.</span> [<a href="/pubmed/24597975" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24597975</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="x-ald.REF.van_roermund.2008.4201">van Roermund CW, Visser WF, Ijlst L, van Cruchten A, Boek M, Kulik W, Waterham HR, Wanders RJ. The human peroxisomal ABC half transporter ALDP functions as a homodimer and accepts acyl-CoA esters. <span><span class="ref-journal">FASEB J. </span>2008;<span class="ref-vol">22</span>:4201–8.</span> [<a href="/pubmed/18757502" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18757502</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="x-ald.REF.vogel.2015.599">Vogel BH, Bradley SE, Adams DJ, D'Aco K, Erbe RW, Fong C, Iglesias A, Kronn D, Levy P, Morrissey M, Orsini J, Parton P, Pellegrino J, Saavedra-Matiz CA, Shur N, Wasserstein M, Raymond GV, Caggana M. Newborn screening for X-linked adrenoleukodystrophy in New York State: Diagnostic protocol, surveillance protocol and treatment guidelines. <span><span class="ref-journal">Mol Genet Metab. </span>2015;<span class="ref-vol">114</span>:599–603.</span> [<a href="/pubmed/25724074" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25724074</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="x-ald.REF.wanders.1998.285">Wanders RJ, Mooyer PW, Dekker C, Vreken P. X-linked adrenoleukodystrophy: improved prenatal diagnosis using both biochemical and immunological methods. <span><span class="ref-journal">J Inherit Metab Dis. </span>1998;<span class="ref-vol">21</span>:285–7.</span> [<a href="/pubmed/9686376" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9686376</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="x-ald.REF.wang.2011.160">Wang Y, Busin R, Reeves C, Bezman L, Raymond G, Toomer CJ, Watkins PA, Snowden A, Moser A, Naidu S, Bibat G, Hewson S, Tam K, Clarke JT, Charnas L, Stetten G, Karczeski B, Cutting G, Steinberg S. X-linked adrenoleukodystrophy: ABCD1 de novo mutations and mosaicism. <span><span class="ref-journal">Mol Genet Metab. </span>2011;<span class="ref-vol">104</span>:160–6.</span> [<a href="/pubmed/21700483" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21700483</span></a>]</div></li></ul></div></div><div id="x-ald.Chapter_Notes"><h2 id="_x-ald_Chapter_Notes_">Chapter Notes</h2><div id="x-ald.Acknowledgments"><h3>Acknowledgments</h3><p>The authors' work is supported by the National Institutes of Health and the Food and Drug Administration.</p></div><div id="x-ald.Author_History"><h3>Author History</h3><p>Corinne D Boehm, MS; Johns Hopkins Hospital (1999-2002)<br />Ali Fatemi, MD (2018-present)<br />Ann B Moser, BA (1999-present)<br />Hugo W Moser, MD; Johns Hopkins University School of Medicine (1999-2007*)<br />Gerald Raymond, MD (2006-present)<br />Steven J Steinberg, PhD; Johns Hopkins University School of Medicine (2002-2018)</p><p>*Hugo W Moser, MD was Professor of Neurology and Pediatrics at Johns Hopkins University School of Medicine and former Director of the Kennedy Krieger Institute in Baltimore. He was a world-renowned expert in the field of neurogenetics. He was best known for his leadership role in understanding, diagnosing, and treating adrenoleukodystrophy (ALD). Dr. Moser died of cancer on January 20, 2007 at age 82. He is greatly missed by his family, friends, colleagues, and patients.</p></div><div id="x-ald.Revision_History"><h3>Revision History</h3><ul><li class="half_rhythm"><div>15 February 2018 (ha) Comprehensive update posted live</div></li><li class="half_rhythm"><div>9 April 2015 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>19 April 2012 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>2 June 2009 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>27 July 2006 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>15 April 2004 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>26 August 2002 (ss) Author revisions</div></li><li class="half_rhythm"><div>26 February 2002 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>26 March 1999 (pb) Review posted live</div></li><li class="half_rhythm"><div>2 February 1999 (hm) Original submission</div></li></ul></div></div><div id="bk_toc_contnr"></div></div></div>
            <div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright</a> © 1993-2019, University of Washington, Seattle. GeneReviews is
a registered trademark of the University of Washington, Seattle. All rights
reserved.<p class="small">GeneReviews® chapters are owned by the University of Washington. Permission is
hereby granted to reproduce, distribute, and translate copies of content materials for
noncommercial research purposes only, provided that (i) credit for source (<a href="http://www.genereviews.org/" ref="pagearea=meta&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">http://www.genereviews.org/</a>) and copyright (© 1993-2019 University of
Washington) are included with each copy; (ii) a link to the original material is provided
whenever the material is published elsewhere on the Web; and (iii) reproducers,
distributors, and/or translators comply with the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>. No further modifications are allowed. For clarity, excerpts
of GeneReviews chapters for use in lab reports and clinic notes are a permitted
use.</p><p class="small">For more information, see the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>.</p><p class="small">For questions regarding permissions or whether a specified use is allowed,
contact: <a href="mailto:dev@null" data-email="ude.wu@tssamda" class="oemail">ude.wu@tssamda</a>.</p></div><div class="small"><span class="label">Bookshelf ID: NBK1315</span><span class="label">PMID: <a href="/pubmed/20301491" title="PubMed record of this page" ref="pagearea=meta&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">20301491</a></span></div><div style="margin-top:2em" class="bk_noprnt"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/x-ag/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/xla/" title="Next page in this title">Next &gt;</a></div></div></div></div>
            
        </div>

        <!-- Custom content below content -->
        <div class="col4">
            
        </div>
        
        
        <!-- Book content -->
        
        <!-- Custom contetnt below bottom nav -->
        <div class="col5">
            
        </div>
    </div>

    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            <div id="ncbi_share_book"><a href="#" class="ncbi_share" data-ncbi_share_config="popup:false,shorten:true" ref="id=NBK1315&amp;db=books">Share</a></div>

        </div>
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Views</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PDF_download" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/NBK1315/?report=reader">PubReader</a></li><li><a href="/books/NBK1315/?report=printable">Print View</a></li><li><a data-jig="ncbidialog" href="#_ncbi_dlg_citbx_NBK1315" data-jigconfig="width:400,modal:true">Cite this Page</a><div id="_ncbi_dlg_citbx_NBK1315" style="display:none" title="Cite this Page"><div class="bk_tt">Raymond GV, Moser AB, Fatemi A. X-Linked Adrenoleukodystrophy. 1999 Mar 26 [Updated 2018 Feb 15]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. <span class="bk_cite_avail"></span></div></div></li><li><a href="/books/NBK1315/pdf/Bookshelf_NBK1315.pdf">PDF version of this page</a> (457K)</li><li><a href="#" class="toggle-glossary-link" title="Enable/disable links to the glossary">Disable Glossary Links</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>In this GeneReview</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="page-toc" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="#x-ald.Summary" ref="log$=inpage&amp;link_id=inpage">Summary</a></li><li><a href="#x-ald.GeneReview_Scope" ref="log$=inpage&amp;link_id=inpage"><i>GeneReview</i> Scope</a></li><li><a href="#x-ald.Diagnosis" ref="log$=inpage&amp;link_id=inpage">Diagnosis</a></li><li><a href="#x-ald.Clinical_Characteristics" ref="log$=inpage&amp;link_id=inpage">Clinical Characteristics</a></li><li><a href="#x-ald.Genetically_Related_Allelic_Disord" ref="log$=inpage&amp;link_id=inpage">Genetically Related (Allelic) Disorders</a></li><li><a href="#x-ald.Differential_Diagnosis" ref="log$=inpage&amp;link_id=inpage">Differential Diagnosis</a></li><li><a href="#x-ald.Management" ref="log$=inpage&amp;link_id=inpage">Management</a></li><li><a href="#x-ald.Genetic_Counseling" ref="log$=inpage&amp;link_id=inpage">Genetic Counseling</a></li><li><a href="#x-ald.Resources" ref="log$=inpage&amp;link_id=inpage">Resources</a></li><li><a href="#x-ald.Molecular_Genetics" ref="log$=inpage&amp;link_id=inpage">Molecular Genetics</a></li><li><a href="#x-ald.References" ref="log$=inpage&amp;link_id=inpage">References</a></li><li><a href="#x-ald.Chapter_Notes" ref="log$=inpage&amp;link_id=inpage">Chapter Notes</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>GeneReviews Links</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/gene/advanced/"><i>GeneReviews</i> Advanced Search</a></li><li><a href="/books/n/gene/glossary/"><i>GeneReviews</i> Glossary</a></li><li><a href="/books/n/gene/resource_mats/">Resource Materials</a> <span class="bk_hlight1">NEW FEATURE</span></li><li><a href="/books/n/gene/updates/">New in <i>GeneReviews</i></a></li><li><a href="/books/n/gene/authors/">Author List</a></li><li><a href="/books/n/gene/prospective_authors/">For Current/Prospective Authors</a></li><li><a href="/books/n/gene/GRpersonnel/"><i>GeneReviews</i> Personnel</a></li><li><a href="/books/n/gene/howto_linkin/">Download/Link to <i>GeneReviews</i></a></li><li><a href="/books/n/gene/contact_us/">Contact Us</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Tests in GTR by Gene</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=215[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">ABCD1</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Related information</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="discovery_db_links" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=omim&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_omim&amp;IdsFromResult=1471952" ref="log$=recordlinks">OMIM</a><div class="brieflinkpop offscreen_noflow">Related OMIM records</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pmc&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pmc_refs&amp;IdsFromResult=1471952" ref="log$=recordlinks">PMC</a><div class="brieflinkpop offscreen_noflow">PubMed Central citations</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pubmed&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pubmed_refs&amp;IdsFromResult=1471952" ref="log$=recordlinks">PubMed</a><div class="brieflinkpop offscreen_noflow">Links to PubMed</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=gene&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_gene&amp;IdsFromResult=1471952" ref="log$=recordlinks">Gene</a><div class="brieflinkpop offscreen_noflow">Locus Links</div></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Similar articles in PubMed</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PBooksDiscovery_RA" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/17532287" ref="ordinalpos=1&amp;linkpos=1&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> [X-linked adrenoleukodystrophy].</a><span class="source">[Ann Endocrinol (Paris). 2007]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> [X-linked adrenoleukodystrophy].<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Aubourg P. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Ann Endocrinol (Paris). 2007 Dec; 68(6):403-11. Epub 2007 May 29.</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/21164268" ref="ordinalpos=1&amp;linkpos=2&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Adrenoleukodystrophy.</a><span class="source">[Endocr Dev. 2011]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Adrenoleukodystrophy.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Cappa M, Bizzarri C, Vollono C, Petroni A, Banni S. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Endocr Dev. 2011; 20:149-160. Epub 2010 Dec 16.</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301604" ref="ordinalpos=1&amp;linkpos=3&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> <i xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">NR0B1-</i>Related Adrenal Hypoplasia Congenita</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> <i xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">NR0B1-</i>Related Adrenal Hypoplasia Congenita<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Achermann JC, Vilain EJ. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/24006547" ref="ordinalpos=1&amp;linkpos=4&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Ornithine Transcarbamylase Deficiency</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Ornithine Transcarbamylase Deficiency<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Lichter-Konecki U, Caldovic L, Morizono H, Simpson K. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301298" ref="ordinalpos=1&amp;linkpos=5&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Dystrophinopathies</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Dystrophinopathies<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Darras BT, Urion DK, Ghosh PS. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li></ul><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed_reviews&amp;uid=20301491" ref="ordinalpos=1&amp;log$=relatedreviews_seeall&amp;logdbfrom=pubmed">See reviews...</a><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed&amp;uid=20301491" ref="ordinalpos=1&amp;log$=relatedarticles_seeall&amp;logdbfrom=pubmed">See all...</a></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Recent Activity</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="recent_activity" id="Shutter"></a></div><div class="portlet_content"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="HTDisplay" class=""><div class="action"><a href="javascript:historyDisplayState('ClearHT')">Clear</a><a href="javascript:historyDisplayState('HTOff')" class="HTOn">Turn Off</a><a href="javascript:historyDisplayState('HTOn')" class="HTOff">Turn On</a></div><ul id="activity"><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=1" href="/portal/utils/pageresolver.fcgi?recordid=5e040f00dd21425a257510ef">X-Linked Adrenoleukodystrophy - GeneReviews®</a><div class="ralinkpop offscreen_noflow">X-Linked Adrenoleukodystrophy - GeneReviews®<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li></ul><p class="HTOn">Your browsing activity is empty.</p><p class="HTOff">Activity recording is turned off.</p><p id="turnOn" class="HTOff"><a href="javascript:historyDisplayState('HTOn')">Turn recording back on</a></p><a class="seemore" href="/sites/myncbi/recentactivity">See more...</a></div></div></div>
        
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script type="text/javascript" src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
<script type="text/javascript">
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>
    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2019-12-25T20:38:08-05:00&amp;Snapshot=%2Fprojects%2Fbooks%2FPBooks@5.22&amp;Host=portal102&amp;ncbi_phid=CE894EF1E040A521000000000240010F&amp;ncbi_session=CE894EF1E040EFF1_0576SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK1315%2F&amp;Db=pmc&amp;folderID=134&amp;Ncbi_App=bookshelf&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="https://www.nih.gov" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
            
            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>
        </div>
    </div>
    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    
    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        </div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=books&amp;ncbi_pdid=book-part&amp;ncbi_acc=NBK1315&amp;ncbi_domain=gene&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/NBK1315/&amp;ncbi_pagename=X-Linked Adrenoleukodystrophy - GeneReviews® - NCBI Bookshelf&amp;ncbi_bookparttype=chapter&amp;ncbi_app=bookshelf" /></noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- CE894EF1E040EFF1_0576SID /projects/books/PBooks@5.22 portal102 v4.1.r585844 Mon, May 06 2019 02:53:16 -->

<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/js/3879255/4121861/3501987/4008961/3893018/3821238/4062932/4123007/4087685/4076480/3921943/3400083/3426610.js" snapshot="books"></script></body>
</html>